CD97 antibodies

CD97 antibodies (or anti-CD97 antibodies) are monoclonal antibodies designed to target CD97 (also known as ADGRE5), an adhesion G-protein-coupled receptor (aGPCR) that is upregulated in various cancers, including glioblastoma (GBM) and acute myeloid leukemia (AML). CD97 is highly expressed on cancer stem cells and tumor cells but has low or undetectable expression in healthy brain tissue, making it an attractive therapeutic target. Researchers at the NYU Grossman School of Medicine have developed human synthetic antibodies against the extracellular region of CD97, particularly targeting the GPCR autoproteolysis-inducing (GAIN) domain. Some of these antibodies, such as clone A8, undergo efficient receptor-mediated internalization and have been utilized to develop antibody-drug conjugates (ADCs) conjugated to cytotoxic payloads like monomethyl auristatin F (MMAF). In preclinical studies, these anti-CD97 ADCs and antibodies have demonstrated potent, selective cell-killing efficacy against GBM and AML cells in vitro, while sparing normal astrocytes and neural stem cells.

Other names

anti-CD97 antibodiesanti-CD-97 antibodiesanti-CD 97 antibodiesanti-CD97 monoclonal antibodiesanti-CD-97 monoclonal antibodiesanti-CD 97 monoclonal antibodies